CRS

Mannheim, Germany – 29. January, 2025

CRS Clinical Research Services is pleased to announce its acquisition by hVIVO Services Limited (“hVIVO”), a rapidly growing specialist CRO and world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials.

The deal marks a significant milestone in CRS’ journey as we join a leading player in the global CRO sector, hVIVO. As part of the hVIVO Group, we will offer expanded services to accelerate clinical trials, including:

    • Enhanced Early Phase Services: Access a broader range of Phase I and inpatient Phase II services, including Human Challenge Trials (11+ challenge models), first-in-human (FIH), SAD/MAD, BE/BA, QTc, DDI, and specialized renal and hepatic impairment trials.
    • State-of-the-Art Facilities: Benefit from hVIVO facility in Canary Wharf, the world’s largest commercial human challenge trial site, featuring 50 quarantine bedrooms, advanced CL-3 laboratory capabilities and outpatient units.
    • Access to Extensive Clinical Site Networks: Our expanded capabilities now support large-scale trials through an extensive network of clinical sites, ensuring seamless execution and robust patient recruitment.
    • Integrated Full-Service Capabilities: CRS clients will benefit from hVIVO’s full-service offering, including Laboratory services, Data Management, Biostatistics, Medical Writing, and consulting in areas such as CMC, Pre-Clinical, Clinical, PK, QA and Regulatory functions.

CRS Berlin will continue to operate as an independent site. CRS Mannheim and CRS Kiel are commited to maintaining a strong partnership with the Berlin Unit as a trusted collaborator and preferred vendor for specialized clinical trials, ensuring seamless support and business continuity for our clients. The existing senior leadership team will remain in place to ensure consistent delivery of our high-quality services and no changes are foreseen for the current study teams. 

Strategic Advantages of the Acquisition

  • Enhanced Capabilities: The integration will bolster CRS’ clinical, regulatory, and drug development services, offering clients a seamless end-to-end solutions.
  • Broader Reach: With access to hViVO’s extensive network and resources, CRS will strengthen its position in key European and global markets.
  • Increased Innovation: The partnership fosters opportunities to incorporate data-driven insights and digital innovations into clinical trial management and patient recruitment strategies.

About hVIVO

hVIVO is a UK headquartered CRO and the world leader in human challenge trials. The hVIVO Group also provides specialist drug development and clinical consultancy services via Venn Life Science (located in France and the Netherlands), virology and immunology laboratory services via hLAB, and clinical field trial services such as patient recruitment and clinical trial site services.

Delivering Greater Value

This acquisition represents a significant milestone in our commitment to delivering innovative, high-quality solutions for our clients.

With combined expertise, resources, and global reach, CRS is poised to offer even more comprehensive services and drive advancements in clinical trials.

Together, we look forward to shaping the future of clinical research and continuing our mission to improve patient outcomes worldwide.

Stay tuned for more updates as we embark on this new chapter.